Explore the sequelae of long COVID, the range genetic therapies designed to target certain cancers, and developments in cystic fibrosis.
Welcome to the January 2023 issue of ReFlections!
You might note some changes in ReFlections’ editorial
team: Dr. Daniel D. Zimmerman is now Ë¿¹ÏÊÓƵAPP’s Chief
Science Advisor, and ReFlections co-editor Dr. Adela
Osman has assumed Dan’s previous position as Head of
Global Medical. For more information, please see page 22.
Three familiar ReFlections authors are returning to our
pages. Dr. John Lefebre, FRCPC, Senior Technical Global
Medical Director, Ë¿¹ÏÊÓƵAPP International, shares his substantial
COVID-19 knowledge in his discussion of the sequelae of
long COVID and its risk to long-term disability portfolios. As our knowledge of human genetics expands, so is the
range genetic therapies designed to target certain cancers.
Dr. Radhika Counsell, Consulting Medical Officer, Ë¿¹ÏÊÓƵAPP UK
Services Limited, weighs in with the newest information
about trends in these immunotherapies. Hilary Henly,
Global Medical Researcher, Strategic Research, Ë¿¹ÏÊÓƵAPP,
provides a detailed review of cystic fibrosis and encourages
insurers to begin contemplating at least limited term cover.
In 2023, the Longer Life Foundation, Ë¿¹ÏÊÓƵAPP’s research collaboration with Washington University School of Medicine in St. Louis, will mark its 25th anniversary. To find out more about the coming year, please see page 21. We trust you will find this issue both interesting and informative. Please do not hesitate to let us know how we can continue to improve ReFlections for you.
In this Issue
